Invention Grant
- Patent Title: Human monoclonal antibodies against orexin receptor type 1
-
Application No.: US15543371Application Date: 2016-01-14
-
Publication No.: US10758615B2Publication Date: 2020-09-01
- Inventor: Alain Couvineau , Thierry Voisin , Pascal Nicole , Bruno Robert , Pierre Martineau , Myriam Chentouf
- Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE PARIS DIDEROT—PARIS 7 , INSTITUT REGIONAL DU CANCER DE MONTPELLIER , UNIVERSITE DE MONTPELLIER
- Applicant Address: FR Paris FR Paris FR Montpellier FR Montpellier
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE),UNIVERSITE PARIS DIDEROT—PARIS 7,INSTITUT REGIONAL DU CANCER DE MONTPELLIER,UNIVERSITE DE MONTPELLIER
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE),UNIVERSITE PARIS DIDEROT—PARIS 7,INSTITUT REGIONAL DU CANCER DE MONTPELLIER,UNIVERSITE DE MONTPELLIER
- Current Assignee Address: FR Paris FR Paris FR Montpellier FR Montpellier
- Agency: W&C IP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@7793fddc
- International Application: PCT/EP2016/050677 WO 20160114
- International Announcement: WO2016/113356 WO 20160721
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/30 ; A61P35/00 ; C12N15/85 ; C07K16/28 ; A61K39/00
Abstract:
The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
Public/Granted literature
- US20180002421A1 HUMAN MONOCLONAL ANTIBODIES AGAINST OREXIN RECEPTOR TYPE 1 Public/Granted day:2018-01-04
Information query
